PipelineReview.com3d
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML
AURORA, CO, USA I November 21, 2024 I OncoVerity, a pioneer in applying advanced bioinformatics to drug development, announced today the closing of a Series A extension financing led by existing ...
PipelineReview.com3d
LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases
BOSTON, MA, USA I November 20, 2024 I LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration ...
PipelineReview.com3d
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans
LONDON, UK I November 21, 2024 I Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces its progress in the ...
PipelineReview.com3d
Avirmax Biopharma Announces First Patient Dosed in Clinical Trial of ABI-110, a Groundbreaking Gene Therapy for Wet AMD Including PCV
HAYWARD, CA, USA I November 21, 2024 I Avirmax Biopharma, Inc., a leader in the development of innovative gene therapies, today announced that the first patient has been successfully dosed in the ...
PipelineReview.com3d
Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies
ROCHESTER, MN, USA I November 20, 2024 I Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration ...
PipelineReview.com3d
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform
TOKYO, Japan & BOSTON, MA, USA I November 20, 2024 I Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, ...